Bausch Health Companies (BHC) has notable insider buying

Bausch Health Companies (T:BHC)

Bausch Health Companies Inc. (BHC) has a high amount of executive buying compared to its large-cap peers over the past three months. According to regulatory filings yesterday, three insiders have invested a total amount of $4,991,391.Richard Urbain De Schutter, a Director, acquired 125,000 Common Shares on a direct ownership basis at a price of $23.960USD through the public market on September 13th, 2018. This represents a $3,892,602 investment into the company's shares and an account share holdings change of greater than 100%.

Paul Herendeen, CFO, acquired 10,000 Common Shares on a direct ownership basis at a price of $22.610 through the public market on September 14th, 2018. This represents a $226,100 investment into the company's shares and an account share holdings change of 10.3%.

Joseph Papa, CEO and Director, acquired 30,000 Common Shares on a direct ownership basis at a price of $22.320USD through the public market on September 14th, 2018. This represents a $872,690 investment into the company's shares and an account share holdings change of 9.2%.

Bausch Health Companies Inc, formerly Valeant Pharmaceuticals International Inc, is a Canada-based company that develops, manufactures and markets a range of branded and generic pharmaceuticals, medical devices and over-the-counter products. It primarily develops products in the therapeutic areas of eye health, gastroenterology and dermatology. Its dermatology products treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis and other dermatoses. It also offers a selection of aesthetic medical devices that address a variety of conditions, including facial wrinkles, acne, pigmentation conditions and laser hair removal, among others. The gastrointestinal (GI) segment offers products that treat GI and hepatologic conditions, including hepatic encephalopathy, irritable bowel syndrome with diarrhea and ulcerative colitis, among others. Its eye health products are marketed in the following categories: Contact Lens, Pharmaceutical Products and Surgical.